stockrow
Friday 6 November 2026
Export INCR’s income statement to Excel — free account
InterCure Ltd.
INCR Healthcare Drug Manufacturers Specialty & Generic
InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.
3.25
0.05
−1.52%
Follow INCR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | 3 | 20 | 70 | 120 | 97 | 66 | 78 | +76.7% | — | — | — | — | |
| Gross margin, % | — | 0.00 | 0.00 | 13.07 | 45.58 | 40.28 | 38.60 | 29.54 | 12.32 | 12.27 | +12.3 pt | ||||||
| EBT | 0 | (2) | (3) | (2) | (12) | 6 | 13 | (17) | (24) | (13) | n/m | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | (69.75) | (58.90) | 8.28 | 10.91 | (17.22) | (35.60) | (16.32) | (16.3) pt | ||||||
| Net income | 0 | 0 | (3) | (2) | (12) | 2 | 13 | (17) | (20) | (11) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.11 | 0.80 | 9.10 | 13.20 | 10.60 | 7.23 | 7.30 | n/m | |||||
| Earnings | 0.01 | (0.09) | (0.19) | (0.07) | (0.46) | 0.20 | 1.50 | (1.85) | (2.00) | (0.95) | n/m | ||||||
| Cash flow | (0.02) | (0.02) | (0.02) | (0.14) | 0.10 | 1.01 | 1.68 | (1.60) | (1.97) | 0.46 | n/m | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.56) | (0.65) | (0.08) | (0.14) | (0.10) | n/m | ||||||
| Free cash flow | (0.02) | (0.02) | (0.02) | (0.14) | 0.10 | 0.44 | 1.04 | (1.68) | (2.11) | 0.36 | n/m | ||||||
| Book value | 0.50 | 0.35 | 0.29 | 3.18 | 3.37 | 18.46 | 17.13 | 13.62 | 11.71 | 10.71 | +40.6% | ||||||
| Shares, m | 13 | 17 | 18 | 23 | 25 | 8 | 9 | 9 | 9 | 11 | (1.7%) | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | 50.92 | 50.92 | 41.20 | 2.22 | 2.46 | 3.00 | 1.72 | 21.8 | |||||
| P/S | — | — | — | 0.00 | 0.00 | 4.21 | 0.27 | 0.09 | 0.11 | 0.06 | 0.7 | ||||||
| P/B | — | — | — | 2.73 | 2.05 | 2.02 | 0.21 | 0.08 | 0.11 | 0.06 | 1.0 | ||||||
| EV/Sales | — | — | — | 0.00 | 0.00 | 3.70 | (0.04) | 0.24 | 0.40 | 0.39 | 0.7 | ||||||
| EV/FCF | — | — | — | 0.00 | 0.00 | 32.90 | (0.47) | (7.05) | (11.46) | (57.90) | (6.3) | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | 0 | 0 | 0 | (3) | 2 | 8 | 15 | (15) | (18) | 5 | n/m | |||||
| Capex | 0 | — | 0 | (8) | (6) | (4) | (6) | (1) | (1) | (1) | +100.1% | ||||||
| Free cash flow | 0 | 0 | 0 | (3) | 2 | 3 | 9 | (15) | (19) | 4 | n/m | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 0 | 0 | (3) | 6 | 15 | 44 | 58 | 52 | 45 | 30 | n/m | |||||
| Net debt | 0 | 0 | 2 | (3) | (10) | (57) | (37) | (2) | 15 | 12 | n/m | ||||||
| Shareholders’ equity | 6 | 6 | 5 | 74 | 86 | 142 | 155 | 124 | 107 | 115 | +38.2% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | 0.98 | (43.41) | (40.62) | (3.74) | (12.66) | 0.92 | 5.36 | (6.74) | (8.73) | (5.10) | (6.1) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.37 | 7.94 | (5.79) | (9.23) | (3.90) | (3.9) pt | ||||||
| ROE | 1.13 | (25.66) | (60.96) | (4.30) | (14.54) | 1.28 | 8.98 | (12.04) | (15.82) | (9.32) | (10.5) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | 350 | 370 | 270 | 320 | 285 | (5.0%) | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.20 | 0.32 | 0.36 | 0.21 | 0.28 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2023 · fundamentals updated 26 Oct 2026
InterCure Ltd. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CPIX Cumberland Pharmaceuticals Inc. | $75.1M | — (loss-making) | — (loss-making) | −98.46% (below 0%: shrinking) | n/m | −82.78% (below 0%: shrinking) | 100.00% | (1,898.20%) | Compare |
| TLPH Talphera, Inc. | $52.4M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −33.11% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CTOR Citius Oncology, Inc. | $46.5M | — (loss-making) | — | — | n/m | 0.00% | 67.07% | (583.53%) | Compare |
| ZYBT Zhengye Biotechnology Holding Limited | $41.0M | — | — | — | — | −69.31% (below 0%: shrinking) | — | — | Compare |
| INCR InterCure Ltd. | $39.1M | 6.2× | — (loss-making) | −6.53% (below 0%: shrinking) | n/m | +389.50% (above 0%: growing) | 32.04% | 0.00% | |
| SCYX SCYNEXIS, Inc. | $32.8M | — (loss-making) | — (loss-making) | −8.56% (below 0%: shrinking) | n/m | −98.60% (below 0%: shrinking) | 100.00% | (3,308.51%) | Compare |
| RMTI Rockwell Medical, Inc. | $30.6M | — (loss-making) | — (loss-making) | +10.63% (above 0%: growing) | n/m | −12.92% (below 0%: shrinking) | 18.24% | (5.97%) | Compare |
| IXHL Incannex Healthcare Inc. | $28.5M | — (loss-making) | — (loss-making) | −92.31% (below 0%: shrinking) | n/m | +327.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CPHI China Pharma Holdings, Inc. | $22.8M | — (loss-making) | — (loss-making) | −7.56% (below 0%: shrinking) | n/m | −113.57% (below 0%: shrinking) | 8.82% | (150.99%) | Compare |
| Median of peers | $36.9M | — | — | −50.43% | — | −51.21% | 100.00% | (150.99%) |